Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-15.01M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -62.91% |
| Return on Assets (Trailing 12 Months) | -53.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.72 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 24.29M |
| Free Float | 21.31M |
| Market Capitalization | $22.80M |
| Average Volume (Last 20 Days) | 0.12M |
| Beta (Past 60 Months) | 1.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.28% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |